Latest News

PREMIUM found prasugrel monotherapy before primary PCI raised ischemic risk vs DAPT in STEMI despite less major bleeding, per ESC Congress 2026 data.

The phase 2 TRANQUILITY trial found the IL-6 antibody pacibekitug produced sustained, dose-dependent reductions in hs-CRP in patients with chronic kidney disease.

Milvexian added to standard antiplatelet therapy did not lower MACE or increase intracranial/fatal bleeding versus placebo after ACS.

The ENRICH-AF trial found edoxaban did not significantly reduce stroke or systemic embolism but increased major bleeding in patients with AF and prior intracranial hemorrhage.

STAREE findings show atorvastatin reduced major cardiovascular events by 30% in older adults without known cardiovascular disease, but disability-free survival was unchanged.

Karolinska Institute's Johannes Blom, MD, PhD, explains why colorectal cancer screening's real-world mortality benefit has been underestimated.

A roundup of the biggest cardiology news out of ESC Congress on day 1, spanning new guidelines, a phase 3 miss, and 2 practice-informing trial readouts.

An individual participant data meta-analysis found antihypertensive therapy reduced cardiovascular events only in patients with at least 80% medication adherence.

The ESC and ERA issued their first joint guideline recommending universal CKD screening and expanded use of risk-modifying therapies in patients with cardiovascular disease.

The updated ESC guidelines make sweeping changes to HF terminology, eliminating HFmrEF and recategorizing acute HF for patients with slower symptom development.

Both apixaban and rivaroxaban resulted in improved risk of stroke, systemic embolism, major bleeding, and cardiovascular death compared to no anticoagulation.

SURPASS-CVOT showed tirzepatide is non-inferior to dulaglutide for cardiovascular events in more than 13,000 adults with type 2 diabetes.

The ESC, ACC, AHA, and WHF jointly replaced numerical MI typing with primary, secondary, and procedure-related categories, announced at ESC Congress 2026.

CARDIO-TTRansform data presented at ESC 2026 showed no significant reduction in cardiovascular mortality or recurrent events with eplontersen versus placebo in ATTR-CM.

The approval adds brepocitinib (Lisraya), an oral JAK/TYK2 inhibitor, as the first agent specifically studied and approved for dermatomyositis in adults.

Brendan Neuen, MBBS, PhD, joins Shikha Wadhwani, MD, MS, to unpack FIND-CKD's GN subgroup data and 23% risk reduction.

Mahboobeh Mahdavinia, MD, PhD, discusses new FORWARD data showing peanut and shellfish allergies resolve far less often than milk, soy, or wheat.

LEADderm 2026 brings dermatology leaders to Newport Beach, California, August 29-30, for sessions on leadership, AI in education, and career growth.

The Phase 3 CROSSING trial showed tezepelumab improved histologic remission and dysphagia symptoms through week 52 in eosinophilic esophagitis.

A phase 2 study found the EAP regimen achieved optimal stem cell mobilization in most patients with multiple myeloma or lymphoma, with low plerixafor need.

Baseline structural damage accounted for most of the variance in placebo-arm radiographic progression across 6 PsA trials.

In this episode of Diabetes Dialogue, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Casey Halpern, MD, to discuss SynchNeuro's investigational, non-invasive EEG-based glucose monitor.

IMPACT-PLuS investigator Jennifer A. Dantzer says predictive biomarkers and formal remission testing remain unanswered questions in peanut OIT.